Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

XC 386: a new antiplatelet agent.

J P Wang, M F Hsu, H Y Tsai

    Thrombosis Research
    |October 15, 1984
    PubMed
    Summary

    XC386 effectively inhibits platelet aggregation and release reactions, particularly those induced by collagen and ADP. This new antiplatelet compound shows promise by acting early in the platelet activation pathway.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A magneto-microfluidic platform for fluorescence immunosensing using quantum dot nanoparticles.

    Nanotechnology·2019
    Same author

    VE/VCO<sub>2</sub> Slope and Functional Capacity in Patients Post-Heart Transplantation.

    Transplantation proceedings·2018
    Same author

    Magnetofluorescent nanocomposites and quantum dots used for optimal application in magnetic fluorescence-linked immunoassay.

    Analytical and bioanalytical chemistry·2018
    Same author

    Detection of c-reactive protein based on a magnetic immunoassay by using functional magnetic and fluorescent nanoparticles in microplates.

    The Analyst·2014
    Same author

    Single nucleotide polymorphisms in the insulin-like growth factor 1 (IGF1) gene are associated with growth-related traits in farmed Atlantic salmon.

    Animal genetics·2014
    Same author

    Prognostic value of oxygen consumption and ventilatory equivalent slope in female candidates referred for heart transplantation--experience of a single Asian center.

    Transplantation proceedings·2014

    Area of Science:

    • Pharmacology
    • Hematology
    • Biochemistry

    Background:

    • Platelet aggregation is a critical process in thrombosis.
    • Developing novel antiplatelet agents is essential for cardiovascular disease management.
    • Understanding the mechanisms of platelet activation is key to drug discovery.

    Purpose of the Study:

    • To investigate the antiplatelet activity of a novel compound, XC386.
    • To determine the mechanism of action of XC386 in inhibiting platelet function.
    • To assess the dose-dependency and specificity of XC386's inhibitory effects.

    Main Methods:

    • Platelet-rich plasma and washed platelet aggregation assays were performed.
    • Inhibition of collagen-, ADP-, thrombin-, A23187-, and arachidonate-induced aggregations was measured.
    • Malondialdehyde (MDA) and thromboxane B2 (TXB2) production were analyzed.
    • Synergistic effects with indomethacin and CP/CPK were evaluated.

    Main Results:

    • XC386 demonstrated dose-dependent inhibition of collagen-induced platelet aggregation (IC50 = 1 mM).
    • It markedly inhibited ADP- and collagen-induced aggregations more than thrombin-, A23187-, or arachidonate-induced ones.
    • XC386 significantly inhibited collagen-, thrombin-, and A23187-induced MDA and TXB2 formation, but not arachidonate-induced formation.
    • High calcium concentrations did not antagonize XC386's inhibitory effect.
    • Combinations with indomethacin or CP/CPK enhanced XC386's inhibitory effects.

    Conclusions:

    • XC386 is a potent antiplatelet compound with a novel mechanism of action.
    • The compound likely inhibits platelet aggregation upstream of arachidonic acid release.
    • XC386 represents a potential therapeutic candidate for preventing thrombotic events.

    Related Experiment Videos